Gaedigk A, Simon S D, Pearce R E, Bradford L D, Kennedy M J, Leeder J S
Section of Developmental Pharmacology and Experimental Therapeutics, Children's Mercy Hospital & Clinics, Kansas City, Missouri, USA.
Clin Pharmacol Ther. 2008 Feb;83(2):234-42. doi: 10.1038/sj.clpt.6100406. Epub 2007 Oct 31.
Inferring CYP2D6 phenotype from genotype is increasingly challenging, considering the growing number of alleles and their range of activity. This complexity poses a challenge in translational research where genotyping is being considered as a tool to personalize drug therapy. To simplify genotype interpretation and improve phenotype prediction, we evaluated the utility of an "activity score" (AS) system. Over 25 CYP2D6 allelic variants were genotyped in 672 subjects of primarily Caucasian and African-American heritage. The ability of genotype and AS to accurately predict phenotype using the CYP2D6 probe substrate dextromethorphan was evaluated using linear regression and clustering methods. Phenotype prediction, given as a probability for each AS group, was most accurate if ethnicity was considered; among subjects with genotypes containing a CYP2D6*2 allele, CYP2D6 activity was significantly slower in African Americans compared to Caucasians. The AS tool warrants further prospective evaluation for CYP2D6 substrates and in additional ethnic populations.
鉴于 CYP2D6 等位基因数量不断增加及其活性范围,从基因型推断 CYP2D6 表型的难度越来越大。这种复杂性在转化研究中构成了挑战,因为基因分型正被视为实现药物治疗个体化的一种工具。为了简化基因型解读并改善表型预测,我们评估了一种“活性评分”(AS)系统的效用。对 672 名主要为高加索和非裔美国血统的受试者的 25 种以上 CYP2D6 等位基因变体进行了基因分型。使用线性回归和聚类方法评估了基因型和 AS 使用 CYP2D6 探针底物右美沙芬准确预测表型的能力。如果考虑种族因素,以每个 AS 组的概率给出的表型预测最为准确;在含有 CYP2D6*2 等位基因的基因型受试者中,非裔美国人的 CYP2D6 活性明显低于高加索人。AS 工具需要对 CYP2D6 底物和更多种族人群进行进一步的前瞻性评估。